Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Primech Holdings (Nasdaq: PMEC) Subsidiary Earns 2026 LowCarbonSG Gold Leader Recognition Following 17.5% Year-on-Year Reduction in Scope 1 and 2 Emissions

October 8, 2026

MBody AI Adds 2 Patents Pending for Its Enterprise AI Workforce Platform

October 8, 2026

CannaSours Ultra Sour Fruit Punch THC Gummies Launch at nuEra Illinois Dispensaries

October 8, 2026

Coinbax Joins the U.S. Faster Payments Council as It Extends Payment Controls to FedNow and RTP

October 8, 2026

Safe Pro Awarded New AI Subcontract and Launches “SPAI Ground Truth” for Next-Gen Ground Intelligence

October 8, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Chemotherapy Induced Peripheral Neuropathy Treatment Market to Surge to $2.06 Billion by 2027, New Research Shows
Press Release

Chemotherapy Induced Peripheral Neuropathy Treatment Market to Surge to $2.06 Billion by 2027, New Research Shows

By News RoomJanuary 23, 20243 Mins Read
Chemotherapy Induced Peripheral Neuropathy Treatment Market to Surge to .06 Billion by 2027, New Research Shows
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) — The “Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering.

The global market for chemotherapy-induced peripheral neuropathy (CIPN) treatments is poised for robust growth, with prospects brightening owing to escalating cancer cases worldwide. A comprehensive research report has been added to our system, providing an in-depth analysis of the CIPN treatment market’s emerging trends, growth drivers, and innovative product developments that are positioned to redefine therapeutic approaches in this niche.

The increase in cancer prevalence significantly propels the demand for chemotherapy, leading to a subsequent uptick in occurrences of CIPN. This condition, characterized by nerve damage arising from chemotherapy agents, has captured the interest of various pharmaceutical players in the healthcare sector, prompting extensive research and development activities aimed at mitigating symptoms and improving quality of life for affected patients.

According to the report, the market is expected to escalate from its valuation of $1.43 billion in 2022 to an impressive $1.54 billion in 2023, reflecting a CAGR of 7.12%. Despite the challenges posed by global scenarios such as the Russia-Ukraine conflict and the ongoing recovery from the COVID-19 pandemic, the need for effective CIPN management courses through, with projections indicating a market size of $2.06 billion by 2027 at a CAGR of 7.57%.

Key Market Trends and Innovations

  • Product innovation remains at the forefront of market expansion, with clinical-stage entities fast-tracking novel candidates aimed at complex pain management related to CIPN.
  • Strategic acquisitions within the sector are enhancing the focus on neuropathic pain indications, thereby broadening the pipeline for potential therapeutic agents.

North America retains its dominance in the CIPN treatment market space, thanks to a robust healthcare structure and significant investment in oncological research. However, the Asia-Pacific and European regions are spotlighted for rapid growth during the forecast period, expanding access and treatment options across varied demographics.

Market Dynamics and Growth Drivers

The necessity to manage and alleviate the debilitating effects of CIPN fuels the market. Boasting an array of pharmaceutical offerings, including pain relievers, antidepressants, anticonvulsants, and topical agents, these therapies are integral to a holistic cancer treatment plan. The predominance of branded drugs alongside generic counterparts characterizes the current market landscape, with availability across hospital and retail pharmacies, as well as online platforms, fostering accessibility for patients and healthcare providers alike.

Key Attributes:

Report Attribute Details
No. of Pages 175
Forecast Period 2023 – 2027
Estimated Market Value (USD) in 2023 $1.54 billion
Forecasted Market Value (USD) by 2027 $2.06 billion
Compound Annual Growth Rate 7.5%
Regions Covered Global

A selection of companies mentioned in this report includes

  • Sanofi SA
  • Bristol Myers Squibb
  • Abbott Laboratories
  • Takeda Pharmaceutical Company
  • Amgen Inc.
  • Asahi Kasei Pharma Corporation
  • Toray Industries
  • Vertex Pharmaceuticals Inc.
  • Alexion Pharmaceuticals Inc.
  • BioMérieux SA
  • Jazz Pharmaceuticals Inc.
  • WEX Pharmaceuticals Inc.
  • Quidel Corporation
  • Laboratories Dr. Esteve S.A. (ESTEVE)
  • Genentech Inc.
  • MediciNova Inc.
  • ChromaDex Corp
  • WinSanTor Inc.
  • Solasia Pharma K.K.
  • NeuroMetrix Inc.
  • Nemus Bioscience Inc.
  • Aphios Corporation
  • Kineta Inc.
  • DARA BioSciences Inc.
  • Aptinyx Inc.
  • Apexian Pharmaceuticals Inc.
  • Krenitsky Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/26n4sk

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Global Chemotherapy Induced Peripheral Neuropathy Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Primech Holdings (Nasdaq: PMEC) Subsidiary Earns 2026 LowCarbonSG Gold Leader Recognition Following 17.5% Year-on-Year Reduction in Scope 1 and 2 Emissions

MBody AI Adds 2 Patents Pending for Its Enterprise AI Workforce Platform

CannaSours Ultra Sour Fruit Punch THC Gummies Launch at nuEra Illinois Dispensaries

Coinbax Joins the U.S. Faster Payments Council as It Extends Payment Controls to FedNow and RTP

Safe Pro Awarded New AI Subcontract and Launches “SPAI Ground Truth” for Next-Gen Ground Intelligence

Philadelphia Poker Dealer Nate Lindquist Wins World Series of Golf x Topgolf Satellite Series Finals

CFPDP to Honour 2026 Inductees at 33rd Annual Canadian Disability Hall of Fame Induction Luncheon

General Fusion, UKAEA Announce Magnetized Target Fusion Milestone

Muon Space Expands Leadership Team as Company Scales Constellation Programs

Editors Picks

MBody AI Adds 2 Patents Pending for Its Enterprise AI Workforce Platform

October 8, 2026

CannaSours Ultra Sour Fruit Punch THC Gummies Launch at nuEra Illinois Dispensaries

October 8, 2026

Coinbax Joins the U.S. Faster Payments Council as It Extends Payment Controls to FedNow and RTP

October 8, 2026

Safe Pro Awarded New AI Subcontract and Launches “SPAI Ground Truth” for Next-Gen Ground Intelligence

October 8, 2026

Latest News

Philadelphia Poker Dealer Nate Lindquist Wins World Series of Golf x Topgolf Satellite Series Finals

October 8, 2026

CFPDP to Honour 2026 Inductees at 33rd Annual Canadian Disability Hall of Fame Induction Luncheon

October 8, 2026

1 in 3 food banks, shelters forced to turn away people due to demand: survey

October 8, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version